(CATX) Perspective Therapeutics - Ratings and Ratios
Alpha-Emitting Radiopharmaceuticals, Targeted Cancer Therapy, Neuroendocrine Tumor Treatment, Metastatic Melanoma Therapy, Prostate Cancer Radiopharmaceutical
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 98.2% |
| Value at Risk 5%th | 143% |
| Relative Tail Risk | -11.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.31 |
| Alpha | -36.08 |
| CAGR/Max DD | 0.02 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.450 |
| Beta | 1.538 |
| Beta Downside | 0.818 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.71% |
| Mean DD | 46.65% |
| Median DD | 44.44% |
Description: CATX Perspective Therapeutics December 30, 2025
Perspective Therapeutics (NASDAQ CATX) develops precision-targeted alpha-particle radiopharmaceuticals for oncology, focusing on tumors that express specific surface receptors. Its lead candidate, VMT-a-NET, is in a Phase 1/2a trial for unresectable or metastatic somatostatin-receptor-2 (SSTR2) positive neuroendocrine tumors that have not received prior peptide-targeted beta therapy such as Lutathera.
Additional pipelines include VMT01 (Phase 1/2a for MC1R-positive metastatic melanoma), PSV359 (fibroblast-activation-protein-alpha-targeted alpha therapy), and PSV4XX (PSMA-targeted alpha therapy for prostate cancer). The company has a clinical-trial collaboration with Bristol Myers Squibb to test [¹²²Pb] VMT01 combined with nivolumab in MC1R-positive melanoma patients.
From a financial-metric standpoint, Perspective reported cash and cash equivalents of roughly $32 million at the end of Q2 2024, giving it an estimated 12-month runway at its current burn rate of $2.5 million per month. The radiopharmaceutical sector is expanding at a compound annual growth rate of ~10 % through 2030, driven by increasing FDA approvals of targeted radionuclide therapies and rising reimbursement comfort.
Key economic drivers for the company include the scarcity of alpha-emitting isotopes (e.g., ²¹²Pb) and the need for scalable production, as well as the broader shift toward precision oncology that favors agents with high tumor-to-normal-tissue dose differentials.
For a deeper quantitative view, you might explore Perspective Therapeutics’ profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-105.8m TTM) > 0 and > 6% of Revenue (6% = 50.5k TTM) |
| FCFTA -0.35 (>2.0%) and ΔFCFTA -25.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.8k% (prev 71.8k%; Δ -53.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.29 (>3.0%) and CFO -84.4m > Net Income -105.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (74.3m) change vs 12m ago 5.19% (target <= -2.0% for YES) |
| Gross Margin -166.3% (prev -14.3k%; Δ 14.1kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.25% (prev 0.09%; Δ 0.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -281.0 (EBITDA TTM -105.2m / Interest Expense TTM 385.0k) >= 6 (WARN >= 3) |
Altman Z'' -7.83
| (A) 0.54 = (Total Current Assets 178.5m - Total Current Liabilities 20.6m) / Total Assets 294.8m |
| (B) -1.01 = Retained Earnings (Balance) -297.4m / Total Assets 294.8m |
| warn (B) unusual magnitude: -1.01 — check mapping/units |
| (C) -0.32 = EBIT TTM -108.2m / Avg Total Assets 343.0m |
| (D) -5.65 = Book Value of Equity -297.2m / Total Liabilities 52.6m |
| Total Rating: -7.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.25
| 1. Piotroski 0.0pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda 0.22 |
| 6. ROIC - WACC (= -50.20)% |
| 7. RoE -39.07% |
| 8. Rev. Trend -88.21% |
| 9. EPS Trend -61.86% |
What is the price of CATX shares?
Over the past week, the price has changed by -2.14%, over one month by +25.57%, over three months by -19.83% and over the past year by -13.79%.
Is CATX a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CATX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.3 | 347.6% |
| Analysts Target Price | 12.3 | 347.6% |
| ValueRay Target Price | 2.7 | -0.4% |
CATX Fundamental Data Overview January 01, 2026
P/S = 189.4754
P/B = 0.8409
Beta = 1.235
Revenue TTM = 841.0k USD
EBIT TTM = -108.2m USD
EBITDA TTM = -105.2m USD
Long Term Debt = 1.58m USD (from longTermDebt, last quarter)
Short Term Debt = 759.0k USD (from shortTermDebt, last quarter)
Debt = 3.31m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.4m USD (from netDebt column, last quarter)
Enterprise Value = 32.9m USD (203.7m + Debt 3.31m - CCE 174.1m)
Interest Coverage Ratio = -281.0 (Ebit TTM -108.2m / Interest Expense TTM 385.0k)
FCF Yield = -317.6% (FCF TTM -104.4m / Enterprise Value 32.9m)
FCF Margin = -12.4k% (FCF TTM -104.4m / Revenue TTM 841.0k)
Net Margin = -12.6k% (Net Income TTM -105.8m / Revenue TTM 841.0k)
Gross Margin = -166.3% ((Revenue TTM 841.0k - Cost of Revenue TTM 2.24m) / Revenue TTM)
Gross Margin QoQ = -270.8% (prev -152.8%)
Tobins Q-Ratio = 0.11 (Enterprise Value 32.9m / Total Assets 294.8m)
Interest Expense / Debt = 1.96% (Interest Expense 65.0k / Debt 3.31m)
Taxrate = 2.58% (-2.10m / -81.4m)
NOPAT = -105.4m (EBIT -108.2m * (1 - 2.58%)) [loss with tax shield]
Current Ratio = 8.66 (Total Current Assets 178.5m / Total Current Liabilities 20.6m)
Debt / Equity = 0.01 (Debt 3.31m / totalStockholderEquity, last quarter 242.2m)
Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -23.4m / EBITDA -105.2m)
Debt / FCF = 0.22 (negative FCF - burning cash) (Net Debt -23.4m / FCF TTM -104.4m)
Total Stockholder Equity = 270.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.89% (Net Income -105.8m / Total Assets 294.8m)
RoE = -39.07% (Net Income TTM -105.8m / Total Stockholder Equity 270.8m)
RoCE = -39.71% (EBIT -108.2m / Capital Employed (Equity 270.8m + L.T.Debt 1.58m))
RoIC = -38.68% (negative operating profit) (NOPAT -105.4m / Invested Capital 272.5m)
WACC = 11.52% (E(203.7m)/V(207.0m) * Re(11.68%) + D(3.31m)/V(207.0m) * Rd(1.96%) * (1-Tc(0.03)))
Discount Rate = 11.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.33%
Fair Price DCF = unknown (Cash Flow -104.4m)
EPS Correlation: -61.86 | EPS CAGR: 0.47% | SUE: 3.03 | # QB: 1
Revenue Correlation: -88.21 | Revenue CAGR: -49.51% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.35 | Chg30d=+0.011 | Revisions Net=-2 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.35 | Chg30d=-0.013 | Revisions Net=-3 | Growth EPS=-11.7% | Growth Revenue=-15.2%
Additional Sources for CATX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle